1. Home
  2. GEVO vs PRTA Comparison

GEVO vs PRTA Comparison

Compare GEVO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$1.90

Market Cap

453.1M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.44

Market Cap

482.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
PRTA
Founded
2005
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
453.1M
482.3M
IPO Year
2010
2013

Fundamental Metrics

Financial Performance
Metric
GEVO
PRTA
Price
$1.90
$9.44
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$6.42
$19.00
AVG Volume (30 Days)
1.8M
377.8K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$711,000.00
$814,000.00
Revenue This Year
$913.54
$1,395.77
Revenue Next Year
$9.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$4.32
52 Week High
$2.95
$15.63

Technical Indicators

Market Signals
Indicator
GEVO
PRTA
Relative Strength Index (RSI) 50.65 55.21
Support Level $1.56 $8.23
Resistance Level $2.14 $9.59
Average True Range (ATR) 0.08 0.55
MACD 0.01 0.10
Stochastic Oscillator 58.70 67.20

Price Performance

Historical Comparison
GEVO
PRTA

About GEVO Gevo Inc.

Gevo Inc is a next-generation diversified energy company committed to fueling America's future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Its technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. The business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: